Direction

Reprogramming and gene therapy

A cell’s identity depends on how it reads its DNA. Partial reprogramming explores whether changing that regulation can restore youthful function while preserving what the cell is supposed to be.

All directions →

Conceptual illustrations created with AI. Research findings are described in the text and linked to their sources.

The next question

How do we restore function without losing cell identity?

Inside the researchMouse retina experiment

In 2020, researchers expressed three reprogramming factors in mouse retinal cells. The work reported axon regeneration after injury and improved vision in aged mice and a mouse glaucoma model.

What this leaves open. A result in the mouse eye does not establish safe, whole-body rejuvenation in humans. Delivery, control and long-term safety remain central questions.

Read the paper ↗Reprogramming to recover youthful epigenetic information and restore visionLu et al. · Nature · 2020

Side by side

The rated projects, compared

Project▲	Promised effect▲	Evidence▲	Stage▲	Strongest case against▲
Armatus Bio	+0.8 years of life	The evidence base is above typical seed-stage biotech because there is a project-specific 2026 Molecular Therapy: Nucleic Acids paper for CMT1A translation support and a project-specific 2026 potency-assay paper.	Late preclinical.	The project could fail for ordinary but serious gene-therapy reasons: animal biodistribution may not predict human delivery, distal Schwann-cell and whole-muscle transduction may remain inadequate, safe dosing windows may be narrow, over-silencing or off-target effects may emerge, and CMC/potency gains may not solve the core biology.
ExoNovaX	+0.8 years of life	The evidence base is early and heavily company-controlled.	This is a development-stage program, not a validated or approved therapy in the supplied evidence.	The strongest skeptical case is that this may remain a familiar regenerative-medicine pattern: heavy patenting, broad platform claims, and promising early uncontrolled or lightly powered signals without decisive placebo-controlled efficacy.
Goda Lab	+3 years of life	Project-specific evidence shows XPRIZE Healthspan milestone recognition and a media description of SHT-sEV therapy, plus strong adjacent lab technology capabilities.	Development-stage and still largely preclinical in the supplied evidence.	The central risk is that the longevity story is ahead of the evidence.
Rejuvenate Bio	+7 years of life	The evidence base is meaningful for a preclinical company but not yet strong for therapeutic validation.	Status is preclinical to IND-enabling.	The project could fail because its headline claims rest on preclinical models, small pilot datasets, and company-forward reporting, while the hardest problems, AAV delivery, manufacturing, reproducibility, and reprogramming safety, remain unresolved; even positive animal signals may not translate into scalable human therapies.
Rejuvenation through Low Frequency	+3 years of life	The strongest feasibility support is a 2025 Aging Cell research article directly on low-frequency ultrasound rejuvenating senescent cells in vitro and in vivo, plus XPRIZE semifinalist and Milestone 1 recognition.	Status is early translational.	The failure case is that the apparent rejuvenation signal is overstated, context-specific, or too fragile to survive translation.
RenewalBio	+5 years of life	The evidence base is mixed and still thin for the company-specific therapeutic claims.	Preclinical.	The strongest failure case is that the core advantages are still largely asserted, not demonstrated in the provided evidence.

Companies

Companies in this direction

Ambition is what a company claims. Independent replication is what others have confirmed. Read the two columns together: the gap between them is where a promise runs ahead of a result.

Company▲	Ambition▲	Independent replication▲	Stage▲	Headquarters▲
199 Biotechnologies 199 Biotechnologies develops epigenetic reprogramming therapies, senolytic polyphenol compounds, and affordable longevity diagnostics.	7	1	–	London, United Kingdom
Altos Labs Altos Labs aims to restore cell health and resilience through cell rejuvenation to reverse disease, injury, and life-related disabilities.	9	4	–	2600 Bridge Parkway, Redwood City, CA 94065
BioViva BioViva is developing AAV and CMV gene therapy platforms to lengthen healthy human lifespans and treat cellular aging.	8	2	–	Seattle, Washington, United States
clock.bio clock.health is building a platform for human rejuvenation by decoding genes that enable cells to reverse aging.	7	1	–	Cambridge, United Kingdom
Dorian Therapeutics	9	0	–	San Francisco, California, United States
General Control General Control engineers epigenetic medicines for the complexity of age-related diseases.	8	0	–	San Francisco, California, United States
Genflow Biosciences Genflow develops SIRT6-based gene therapies intended to slow aging and extend healthy lifespan in humans and dogs.	7	3	public	London, United Kingdom; Belgium, Netherlands
Junevity Junevity develops siRNA therapeutics to reset dysregulated gene networks and reverse complex age-related diseases.	8	1	–	San Francisco, California, United States
Life Biosciences Life Biosciences is a biotechnology company pioneering cellular rejuvenation using epigenetic restoration to reverse diseases of aging.	9	1	series c plus	Boston, MA
Mogrify Mogrify develops in vivo reprogramming therapies to restore lost cell types and organ function directly in situ.	8	2	series a	Cambridge, United Kingdom
Rejuvenate Bio Rejuvenate Bio develops gene therapy treatments for chronic, age-related diseases in companion animals and humans.	8	3	series a	San Diego, CA
Shift Bioscience Shift Bioscience develops cellular rejuvenation therapies targeting aging cells, including anti-fibrotic siRNA therapeutics for age-driven diseases.	8	1	–	Cambridge (UK)
Telocyte Telocyte seeks to cure Alzheimer's differently by targeting cell aging and telomerase-related gene expression.	8	0	–	United States
Youthereum Genetics Youthereum Genetics sought to fund epigenetic rejuvenation research using an ICO-based decentralized biotech crowdfunding model.	8	0	–	–

Projects

Projects in this direction

Project▲	Stage▲	Strongest case against▲
Armatus Bio Armatus Bio is a U.S. late-preclinical biotech developing AAV-delivered engineered microRNA therapies for autosomal dominant neuromuscular diseases, with lead programs in CMT1A and FSHD.	Late preclinical.	The project could fail for ordinary but serious gene-therapy reasons: animal biodistribution may not predict human delivery, distal Schwann-cell and whole-muscle transduction may remain inadequate, safe dosing windows may be narrow, over-silencing or off-target effects may emerge, and CMC/potency gains may not solve the core biology.
Exomed Exomed appears to be an exosome-centered longevity/regenerative project, but the project identity is unusually muddy: the evidence mixes a broad therapeutic-delivery platform pitch, skin/scalp regeneration marketing, a PRP-to-exosome kit, legacy Australian GI-related patents, and an older Australian company record that was cancelled in 2014.	Status is early and evidentially weak.	The project may fail because the evidence currently looks more like branding plus field-level promise than product proof: exosome identity and purity remain hard to standardize, therapeutic mechanisms are often underspecified, project identity is inconsistent, manufacturing and regulatory burdens are high, and the provided record contains no strong project-specific efficacy evidence.
ExoNovaX ExoNovaX appears to map to Kangstem Biotech, a South Korean regenerative-medicine company developing allogeneic umbilical-cord-blood-derived mesenchymal stem cell products, organoid platforms, and related manufacturing capabilities.	This is a development-stage program, not a validated or approved therapy in the supplied evidence.	The strongest skeptical case is that this may remain a familiar regenerative-medicine pattern: heavy patenting, broad platform claims, and promising early uncontrolled or lightly powered signals without decisive placebo-controlled efficacy.
Goda Lab Goda Lab’s longevity-facing program appears to center on engineered small extracellular vesicles (sEVs) for healthspan restoration, with the strongest project-specific signal coming from XPRIZE Healthspan recognition and a secondary-media description of “SHT-sEV therapy.” The core idea is plausible but still weakly validated in the provided evidence: the lab has strong technical depth in imaging, microfluidics, and cell analysis, yet the actual anti-aging therapeutic claims remain mostly self-described or media-described, with explicit unresolved risks around off-target accumulation, safety, and scalable manufacturing.	Development-stage and still largely preclinical in the supplied evidence.	The central risk is that the longevity story is ahead of the evidence.
Hoskinson Health and Wellness Clinic Hoskinson Health and Wellness Clinic is a Wyoming multi-specialty clinic that presents itself as a longevity- and regenerative-medicine-enabled care model, combining routine clinical services with in-house aging research, specialty care, and claimed regenerative offerings such as PRP, stem-cell-related work, and hyperbaric treatments.	The project appears to have launched in 2022 and expanded rapidly through 2025, but by January 2026 it had cut about 40 jobs amid declining reimbursement and high costs, and on May 22, 2026 clinic leadership announced plans to close, saying it was no longer financially sustainable in its current form.	The evidence also supports a harsher reading: this may have been an overextended founder-driven clinic that mixed ordinary healthcare delivery with ambitious longevity and regenerative marketing before demonstrating durable economics or strong independent clinical evidence.
Marcus STAMINA Team Marcus STAMINA Team appears to be a U.S.-based geroscience pilot centered on whether intermittent dasatinib plus quercetin can be feasibly given to older adults with slow gait speed and mild cognitive impairment as a senolytic strategy aimed at mobility and cognition; the strongest direct evidence is a 2023 rationale-and-design paper for a 12-week, single-arm, open-label feasibility study in 12 participants, which supports serious academic sponsorship but not efficacy.	Early clinical feasibility stage.	The downside case is that the project is overinterpreting a mechanistic aging hypothesis from weak clinical footing: the direct study evidence is only a small, single-arm feasibility design, so apparent benefits could be placebo, regression to the mean, measurement noise, or selection effects, while dasatinib plus quercetin may prove too hard to tolerate, too nonspecific, or too biologically blunt to deliver meaningful functional benefit in an older impaired population.
Mito-tags Mito-tags appears to be a Stanford/VA-linked mitochondrial delivery project built around bio-modified mitochondria for targeted administration to cells.	Early and still evidence-thin.	The failure case is that the project is mostly ambitious IP plus competition visibility: targeted mitochondrial delivery may prove too hard to manufacture, control, scale, or validate biologically, and the current evidence does not yet show that the platform works safely or meaningfully better than simpler alternatives.
Precision Tuning of Endogenous TERT in Mesenchymal Stem Cells for Safe Cellular Rejuvenation This project proposes a safer alternative to blunt telomerase overexpression in mesenchymal stem cells by engineering endogenous TERT regulation as a graded "dimmer switch," aiming to modestly raise telomerase output while preserving native control, stem-cell identity, and genomic stability.	Concept stage.	The failure case is that TERT is too tightly coupled to cancer-relevant and cell-state-relevant programs for safe partial tuning to be reliable in practice.
Prometheus Cell Team Prometheus Cell Team is presented in 2025 media and social sources as a Shanghai-based XPRIZE Healthspan semifinalist developing autologous “Prometheus Cells” by epigenetically reprogramming patient skin fibroblasts into stem cell-like regenerative cells intended to modulate immunity and promote tissue repair.	External recognition is better supported than technical validation.	The most likely failure mode is that the project is ahead on narrative and recognition but behind on hard evidence.
Rejuvenate Bio Rejuvenate Bio is a San Diego startup developing one-time AAV gene therapies for age-related and chronic disease, with the clearest disclosed programs in canine mitral valve disease, desmoplakin arrhythmogenic cardiomyopathy, and partial epigenetic reprogramming.	Status is preclinical to IND-enabling.	The project could fail because its headline claims rest on preclinical models, small pilot datasets, and company-forward reporting, while the hardest problems, AAV delivery, manufacturing, reproducibility, and reprogramming safety, remain unresolved; even positive animal signals may not translate into scalable human therapies.
Rejuvenation through Low Frequency UT Health San Antonio’s "Rejuvenation Through Low Frequency Ultrasound" project is a US-based translational longevity effort testing whether low-frequency ultrasound can reverse cellular senescence without destroying cells.	Status is early translational.	The failure case is that the apparent rejuvenation signal is overstated, context-specific, or too fragile to survive translation.
RenewalBio RenewalBio is an Israel-based Weizmann spinout and startup developing "stembroids": human iPSC-derived developmental models intended to generate DNA-matched transplantable cells and tissues, with the clearest near-term stated target being hematopoietic stem cell applications for bone marrow failure and related transplant settings.	Preclinical.	The strongest failure case is that the core advantages are still largely asserted, not demonstrated in the provided evidence.
The EBIMA Trial The EBIMA Trial appears to sit in a University of Miami clinical-research setting and, based on the evidence provided around mesenchymal-stem-cell and exosome therapeutics, is best understood as a patient-facing regenerative or immunomodulatory therapy project rather than a basic-science effort.	Status is underdetermined.	The failure case is stronger than the hype: the supplied evidence is dominated by patents and general institutional context, not direct trial data, and exosome or stem-cell platforms still face basic risks in product heterogeneity, scale-up, potency measurement, delivery, and real-world efficacy.
Unlimited Bio Unlimited Bio is a promotional longevity startup centered on experimental combination gene therapies, especially VEGF and follistatin, with additional planned programs around KLOTHO, BDNF, PGC-1alpha, and hTERT.	The project appears active at the level of public positioning, partner signaling, and claimed recruitment for follistatin and VEGF plus follistatin programs, but the evidence provided does not show peer-reviewed efficacy data, controlled human outcomes, named study publications, or independently verified clinical results.	Unlimited Bio could fail because the current evidence base is largely promotional, the claims are broader than the demonstrated support, multi-gene delivery may prove unsafe or too hard to control, and access-oriented offshore deployment may generate regulatory and credibility risk before convincing efficacy data exists.

People

People in this direction

Chronology

What happened, and when

Forecasts

What the forecasts expect here

All forecasts →